AP889A - Use of Tricyclic 1,4-dihydro-1,4-dioxo-1h-naphthalene derivatives, resulting novel compounds and therapeutical use thereof. - Google Patents

Use of Tricyclic 1,4-dihydro-1,4-dioxo-1h-naphthalene derivatives, resulting novel compounds and therapeutical use thereof. Download PDF

Info

Publication number
AP889A
AP889A APAP/P/1998/001275A AP9801275A AP889A AP 889 A AP889 A AP 889A AP 9801275 A AP9801275 A AP 9801275A AP 889 A AP889 A AP 889A
Authority
AP
ARIPO
Prior art keywords
dihydro
dioxo
naphtho
thiazole
substituted
Prior art date
Application number
APAP/P/1998/001275A
Other languages
English (en)
Other versions
AP9801275A0 (en
Inventor
Odile Boutherin-Falson
Stephanie Desquand-Billiald
Anita Favrou
Michel Finet
Oliver Tembo
Jean-Luc Torregrosa
Sylvie Yannic-Arnoult
Marquer Florence Domagala-Le
Original Assignee
Laboratoire Innothera Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Innothera Sa filed Critical Laboratoire Innothera Sa
Publication of AP9801275A0 publication Critical patent/AP9801275A0/xx
Application granted granted Critical
Publication of AP889A publication Critical patent/AP889A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
    • C07C225/30—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of condensed quinone ring systems formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C46/00—Preparation of quinones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/24—Quinones containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/32—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/60—Naphthoxazoles; Hydrogenated naphthoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/84—Naphthothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/1998/001275A 1995-12-12 1996-12-10 Use of Tricyclic 1,4-dihydro-1,4-dioxo-1h-naphthalene derivatives, resulting novel compounds and therapeutical use thereof. AP889A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9514683A FR2742153B1 (fr) 1995-12-12 1995-12-12 Utilisation de derives tricycliques du 1,4-dihydro-1,4- dioxo-1h-naphtalene, nouveaux composes obtenus et leur application en therapeutique
PCT/FR1996/001973 WO1997021684A1 (fr) 1995-12-12 1996-12-10 Utilisation de derives tricycliques du 1,4-dihydro-1,4-dioxo-1h-naphtalene, nouveaux composes obtenus et leur application en therapeutique

Publications (2)

Publication Number Publication Date
AP9801275A0 AP9801275A0 (en) 1998-06-30
AP889A true AP889A (en) 2000-11-17

Family

ID=9485393

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1998/001275A AP889A (en) 1995-12-12 1996-12-10 Use of Tricyclic 1,4-dihydro-1,4-dioxo-1h-naphthalene derivatives, resulting novel compounds and therapeutical use thereof.

Country Status (26)

Country Link
US (1) US6262095B1 (fr)
EP (1) EP0876356B1 (fr)
JP (1) JP2000501724A (fr)
KR (1) KR19990072080A (fr)
AP (1) AP889A (fr)
AR (1) AR005054A1 (fr)
AT (1) ATE207907T1 (fr)
AU (1) AU716199B2 (fr)
BR (1) BR9611935A (fr)
CA (1) CA2240279A1 (fr)
CZ (1) CZ181198A3 (fr)
DE (1) DE69616598D1 (fr)
EE (1) EE9800174A (fr)
FR (1) FR2742153B1 (fr)
HU (1) HUP9901247A3 (fr)
ID (1) ID16081A (fr)
IL (1) IL124558A0 (fr)
LT (1) LT4491B (fr)
LV (1) LV12188B (fr)
NO (1) NO982696L (fr)
NZ (1) NZ323967A (fr)
OA (1) OA10696A (fr)
PL (1) PL327168A1 (fr)
RU (1) RU2178791C2 (fr)
TR (1) TR199801069T2 (fr)
WO (1) WO1997021684A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003999A (en) * 1997-12-19 1999-07-12 Advanced Research And Technology Institute, Inc. Modulators of ryanodine receptors comprising 2-(aryl)-4,7-dioxobenzothiazoles and analogues thereof
AU2002231139B2 (en) * 2000-12-21 2007-03-22 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
TWI402261B (zh) 2006-06-19 2013-07-21 Takeda Pharmaceutical 三環化合物及其醫藥組成物
WO2007149484A2 (fr) 2006-06-20 2007-12-27 Dana-Farber Cancer Institute Inhibiteurs de complexe enzymatique provoquant la désubiquitination du usp1
WO2011137320A2 (fr) 2010-04-30 2011-11-03 Dana-Farber Cancer Institute, Inc. Inhibiteurs de petites molécules de l'activité de l'enzyme de déubiquination usp1
US9040713B2 (en) * 2010-09-27 2015-05-26 Emory University Methods of managing blood sugar levels and compositions related thereto
US9725425B1 (en) 2014-02-25 2017-08-08 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
RU2545091C1 (ru) * 2014-03-18 2015-03-27 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Российской академии медицинских наук (ФГБУ "РОНЦ им. Н.Н. Блохина" РАМН) 1-R-4,9-ДИОКСО-1H-НАФТО[2,3-d][1,2,3]ТРИАЗОЛ-4-ОКСИМ-2-ОКСИДЫ И ИХ ПРОИЗВОДНЫЕ, ОБЛАДАЮЩИЕ ЦИТОТОКСИЧЕСКОЙ АКТИВНОСТЬЮ
US10829427B2 (en) 2015-12-18 2020-11-10 The Board Of Regents Of The University Of Texas System Naphthoquinones, pro-drugs, and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019211A2 (fr) * 1991-05-08 1992-11-12 The Upjohn Company Imidazobenzoquinones et composition contenant ces dernieres permettant de prevenir ou de traiter l'hypertension ou l'insuffisance cardiaque

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3039925A (en) 1957-04-24 1962-06-19 Bayer Ag Compositions for the treatment of tuberculosis
US4746676A (en) 1984-09-12 1988-05-24 Rorer Pharmaceutical Corporation Carboxyalkyl dipeptide compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019211A2 (fr) * 1991-05-08 1992-11-12 The Upjohn Company Imidazobenzoquinones et composition contenant ces dernieres permettant de prevenir ou de traiter l'hypertension ou l'insuffisance cardiaque

Also Published As

Publication number Publication date
ATE207907T1 (de) 2001-11-15
BR9611935A (pt) 1999-05-18
DE69616598D1 (de) 2001-12-06
AR005054A1 (es) 1999-04-07
HUP9901247A3 (en) 2000-08-28
CZ181198A3 (cs) 1998-09-16
FR2742153A1 (fr) 1997-06-13
NO982696D0 (no) 1998-06-11
LV12188B (en) 1999-07-20
EP0876356A1 (fr) 1998-11-11
NZ323967A (en) 2000-06-23
OA10696A (fr) 2002-11-26
FR2742153B1 (fr) 1998-02-13
JP2000501724A (ja) 2000-02-15
ID16081A (id) 1997-09-04
IL124558A0 (en) 1998-12-06
US6262095B1 (en) 2001-07-17
NO982696L (no) 1998-08-11
AP9801275A0 (en) 1998-06-30
EE9800174A (et) 1998-12-15
RU2178791C2 (ru) 2002-01-27
PL327168A1 (en) 1998-11-23
WO1997021684A1 (fr) 1997-06-19
AU1101897A (en) 1997-07-03
CA2240279A1 (fr) 1997-06-19
KR19990072080A (ko) 1999-09-27
LV12188A (lv) 1998-12-20
LT4491B (lt) 1999-04-26
HUP9901247A2 (hu) 1999-08-30
LT98085A (en) 1998-11-25
TR199801069T2 (xx) 1998-08-21
EP0876356B1 (fr) 2001-10-31
AU716199B2 (en) 2000-02-24

Similar Documents

Publication Publication Date Title
Moon et al. Synthesis and structure–activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities
AP889A (en) Use of Tricyclic 1,4-dihydro-1,4-dioxo-1h-naphthalene derivatives, resulting novel compounds and therapeutical use thereof.
TW504503B (en) Pyrrole derivatives and the pharmaceutical composition
Rao et al. Synthesis and biological evaluation of novel flavone/triazole/benzimidazole hybrids and flavone/isoxazole-annulated heterocycles as antiproliferative and antimycobacterial agents
AU2018341781B2 (en) Fused ring derivative as A2A receptor inhibitor
US20050250836A1 (en) Inhibitors of checkpoint kinases (Wee1 and Chk1)
JPS61200991A (ja) スピロ―３―ヘテロアゾリジン化合物、その製法及びそれを有効成分とする糖尿病合併症の予防及び治療剤
KR20180066985A (ko) 티에노피리미딘 유도체 및 이의 용도
JPH07507771A (ja) Ｎ−置換アザビシクロヘプタン−誘導体，その製造および使用
CN111704646B (zh) 甾体类化合物及其制备方法和用途
AU2017220984B2 (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
FI95259B (fi) Menetelmä farmaseuttisesti aktiivisten 7-substituoitu-2-amino-3,5-dihydro-4H-pyrrolo/3,2-d/pyrimidin-4-onien valmistamiseksi
CA2974697A1 (fr) Derives de pyrimidine-2,4-(1h,3h)-dione, compositions pharmaceutiques connexes et utilisation comme inhibiteurs des transporteurs de monocarboxylate
Hayallah et al. Design and synthesis of new pyrido [2, 3-d] pyrimidine-1, 4-dione derivatives as anti-inflammatory agents
Kosychova et al. Synthesis of Substituted 5, 6-Dihydro-4H-[1, 2, 4] triazolo [4, 3-a][1, 5] benzodiazepines
Voskressensky et al. A novel domino condensation—intramolecular nucleophilic cyclization approach toward annulated imidazo-pyrrolopyridines
US20090143380A1 (en) 2h- or 3h-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof
RU2502738C2 (ru) 1,6'-ДИАРИЛ-3-АРОИЛ-4-ГИДРОКСИ-1',3'-ДИМЕТИЛСПИРО[ПИРРОЛ-2,5'-ПИРРОЛО[2,3-d]ПИРИМИДИН]-2',4',5(1Н,1'Н,3'Н)-ТРИОНЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
Hamza et al. Synthesis and in vitro anticancer evaluation of novel pyridine derivatives bearing tetrahydronaphthalene scaffold
Abdel-Motaal et al. Synthesis and in vitro Anticancer Activity of Novel Heterocycles Utilizing Thiophene Incorporated Thioureido Substituent as Precursors.
CN111164087B (zh) 有助于抑制人三叶因子3的化合物
Mabkhot et al. Expeditious and highly efficient protocol for the synthesis of novel diversely substituted thieno [2, 3-b] thiophene
JP2022516922A (ja) フッ素含有置換ベンゾチオフェン化合物ならびにその医薬組成物および応用
CN106573917A (zh) 合成氟氯氮平及其衍生物的方法
Khalifa et al. Novel synthesis of pyrazole-containing thiophene, 2-alkyloxy-pyridine and thieno [2, 3-d] pyrimidine scaffolds as analgesic agents